Foundayo daily pill becomes available through UK private pharmacies

Private availability gives eligible patients another route to a medicine that addresses weight management and, in some cases, blood-sugar control. The practical distinction is that Foundayo is taken orally rather than injected, which may matter for people unable or unwilling to use jabs. However, private supply does not settle whether the medicine will be available through the NHS in England. The article also highlights a safety issue: tablet forms may be easier to counterfeit than injectables, so patients need reliable prescribing and dispensing channels rather than unregulated sellers.

Foundayo enters a UK market in which GLP-1 medicines are already used in injectable forms and in which access to weight-management services varies by area. The Guardian reports that the MHRA approved a tablet form of Wegovy for weight loss in June, making Foundayo the second oral GLP-1 option mentioned in the report. Its initial private-prescription route means access will not yet be the same as NHS provision. The National Pharmacy Association called for greater use of pharmacies to help eligible patients obtain treatment through the NHS, citing what it described as a postcode lottery in GP-linked weight-management services. Meanwhile, regulators and manufacturers face an illicit market: the report says the MHRA seized £250,000-worth of unlicensed weight-loss pens and ingredients from a Northampton factory last year.

The reported authorisation and pharmacy launch do not establish that Foundayo will be funded or routinely available on England’s NHS. NICE is still assessing the medicine, and the article gives no timetable or outcome for that process. Eligibility is also restricted by the licence criteria described in the report, rather than applying to everyone seeking weight-loss treatment. In addition, the report does not provide comparative clinical results, pricing, side-effect information, or evidence about how many pharmacies will supply it. Those omissions limit conclusions about uptake, affordability and real-world outcomes.